Skip to main content

Table 1 Baseline demographics, apolipoprotein E status and cerebrospinal fluid markers in the cross-sectional population by baseline status

From: Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database

Baseline status

Control subjects (n = 157)

SMC/MCI (n = 396)

AD (n = 124)

Male sex

77 (49%)

204 (52%)

72 (58%)

Age, years

74 ± 6

72 ± 7a

75 ± 8

ApoE4 carriers

42 (27%)

186 (47%)b

82 (66%)c

Baseline cognition

 GDS

0.7 ± 1.1

1.4 ± 1.4b

1.7 ± 14c

 MMSE

29 ± 1

27 ± 3b

23 ± 2c

 CDR 0

157 (100%)

96 (24%)b

0c

 CDR 0.5

0

299 (76%)a

53 (43%)c

 CDR ≥1

0

1 (0.3%)

71 (57%)c

 ADAS-cog

9 ± 5

16 ± 10b

31 ± 8c

Baseline CSF

 Aβ1–42, ng/L

196 ± 50

175 ± 53b

137 ± 38c

 Tau, ng/L

67 ± 34

88 ± 54b

133 ± 65c

 p-Tau181, ng/L

33 ± 16

43 ± 26b

60 ± 35c

 p-Tau181/Aβ1–42

0.19 ± 0.13

0.29 ± 0.24b

0.48 ± 0.32c

  1. Abbreviations: Aβ Amyloid-β1–42, AD Alzheimer’s disease, ADAS-cog Alzheimer’s Disease Assessment Scale–Cognitive Subscale, ApoE Apolipoprotein E, CDR Clinical Dementia Rating, GDS Geriatric Depression Scale, MCI Mild cognitive impairment, MMSE Mini Mental State Examination, p-tau Phosphorylated tau, SMC Significant memory complaint
  2. a p < 0.01 vs control subjects
  3. b p < 0.001 vs control subjects
  4. c p < 0.001 vs patients with SMC/MCI